Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : The Trump Presidency -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (75420)	6/5/2018 3:18:52 AM
From: i-node	1 Recommendation Recommended By Brian Sullivan Respond to of 356112

Actually, CRISPR-CAS9 is already being used in immunotherapy processes. There are at least a couple of companies working on out-of-the-vial CAR-T solutions which would eliminate the need for processing the patient's T Cells. Potentially really big break through. On the horizon is a second generation of CRISPR that could cut DNA arbitrarily (or more so), which would allow for much greater flexibility. It is a great time to be alive.